Orchard Therapeutics plc EBIT

As of the most recent data (September 2023), ORTX shows a EBIT of $62M. That compares with $-130M in the prior-year period — up 147.3% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ORTX's EBIT is now $62M (was $-130M) — a 147.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Orchard Therapeutics plc is outperforming or lagging.

The Healthcare sector average EBIT is about $23B. Orchard Therapeutics plc is at $62M, which is lower that average. That is roughly 99.7% below the sector mean. Use the comparison chart on this page to see how ORTX stacks up against individual peers as well.

Tracking ORTX's ebit over time shows whether Orchard Therapeutics plc is scaling, shrinking, or reshaping that part of the business. The current reading is $62M That compares with $-130M in the prior-year period — up 147.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Orchard Therapeutics plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $62M) with ownership activity and broader fundamentals.